About Us
The GCH Office of Child Health Research is the central coordination entity, which supports the overall vision of the hospital to conduct research that contributes to the global body of knowledge and advances public policy in response to the real needs of the pediatric population in the developing world.
- GCH Primary Areas of Interest
- ➢ Hemato-oncology
- ➢ Genetics
- ➢ Endocrinology, Diabetes
- ➢ Infectious Diseases
- ➢ Nephrology
- ➢ Neurological Disorders
- ➢ Developmental Disorders
- ➢ Cardiology
- ➢ Audiology
Research Therapeutic Areas Team Leads
| Therapeutic Lead | Therapeutic Area |
| Prof. Jessie Githang’a | Hemato-oncology |
| Dr. Doreen Karimi | Hemato-oncology |
| Dr. Sam Gwer | Neurological Disorders |
| Dr. Joseph Mbuthia | Infectious Diseases |
| Dr. Doris Kinuthia | Nephrology |
| Dr. Catherine Mutinda | Genetics |
| Dr. Renson Mukhwana | Endocrinology, Diabetes |
| Dr. Florence Oringe | Developmental Disorders |
| Dr. Sean Del Rosse | Cardiology |
| Dr. Mark Awori | Cardiology |
Clinical Trials Experience
2012:TADO – A phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and
Placebo in Pediatric Patients with Sickle Cell Disease
2015/2016: HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic
(PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized,
Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with
Sickle Cell Disease
2017:GBT 031 – A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study of GBT
440 Administered Orally to Patients with Sickle Cell Disease
2018:GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to
Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
(GBT440-034)
2018:HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate
Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months,
with Sickle Cell Disease
2019:HESTIA 3 – A Randomised, Double-Blind, Parallel-Group, Multi-centre, Phase 3 Study to
Evaluate the Effect of Ticagrelor vs Placebo in Reducing the Rate of Vaso-Occlusive Crises
in Pediatric Patients with Sickle Cell Disease
2020:IMARA – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with
Sickle Cell Disease
Resources
i. Research4Life
ii. TCC Africa
■ Open Access Research Discoveries Solutions
✓ R Discovery
✓ SciELO
✓ Open Research Library
✓ Dimensions
✓ Meta
✓ CORE
✓ Lens.org
✓ Scienceopen
■ Open Access Repositories
✓ African Digital Research Repositories
✓ AfricArXiv
■ Journal Selection Strategy:
✓ African Journals Online
✓ Directory of Open Access Journals
✓ Dimensions
✓ Lens.org